PL2205281T3 - Koniugaty białko-polimer - Google Patents

Koniugaty białko-polimer

Info

Publication number
PL2205281T3
PL2205281T3 PL08797971.2T PL08797971T PL2205281T3 PL 2205281 T3 PL2205281 T3 PL 2205281T3 PL 08797971 T PL08797971 T PL 08797971T PL 2205281 T3 PL2205281 T3 PL 2205281T3
Authority
PL
Poland
Prior art keywords
protein
polymer conjugates
conjugates
polymer
Prior art date
Application number
PL08797971.2T
Other languages
English (en)
Inventor
Ko-Chung Lin
Original Assignee
Pharmaessentia Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40351178&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2205281(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaessentia Corp. filed Critical Pharmaessentia Corp.
Publication of PL2205281T3 publication Critical patent/PL2205281T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K17/08Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL08797971.2T 2007-08-16 2008-08-15 Koniugaty białko-polimer PL2205281T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95627307P 2007-08-16 2007-08-16
PCT/US2008/073290 WO2009023826A1 (en) 2007-08-16 2008-08-15 Protein-polymer conjugates

Publications (1)

Publication Number Publication Date
PL2205281T3 true PL2205281T3 (pl) 2022-12-12

Family

ID=40351178

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08797971.2T PL2205281T3 (pl) 2007-08-16 2008-08-15 Koniugaty białko-polimer

Country Status (30)

Country Link
US (1) US8143214B2 (pl)
EP (2) EP2205281B1 (pl)
JP (1) JP5613050B2 (pl)
KR (1) KR101588465B1 (pl)
CN (1) CN101367872B (pl)
AR (1) AR067964A1 (pl)
AU (1) AU2008286742B2 (pl)
BR (1) BRPI0814482B8 (pl)
CA (1) CA2696478C (pl)
CL (1) CL2008002399A1 (pl)
CY (1) CY1125751T1 (pl)
DK (1) DK2205281T3 (pl)
EA (1) EA018111B1 (pl)
ES (1) ES2924727T3 (pl)
FR (1) FR22C1045I2 (pl)
HR (1) HRP20220937T3 (pl)
HU (2) HUE059551T2 (pl)
LT (1) LT2205281T (pl)
MX (1) MX2010001750A (pl)
MY (1) MY149148A (pl)
NL (1) NL301195I2 (pl)
NO (1) NO2022038I1 (pl)
NZ (1) NZ583831A (pl)
PL (1) PL2205281T3 (pl)
PT (1) PT2205281T (pl)
SI (1) SI2205281T1 (pl)
TW (1) TWI381851B (pl)
UA (1) UA103158C2 (pl)
WO (1) WO2009023826A1 (pl)
ZA (1) ZA201001777B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009276458B2 (en) * 2008-07-31 2014-06-19 Pharmaessentia Corp. Peptide-polymer conjugates
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
SI3215193T1 (sl) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dozirna shema za pegiliran interferon
CN112433048A (zh) * 2020-11-17 2021-03-02 深圳上泰生物工程有限公司 一种用于化学发光免疫法的试剂盒及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
MXPA02001969A (es) * 1999-08-27 2003-07-21 Maxygen Aps Nuevas moleculas similares a interferon beta.
SK8292002A3 (en) * 1999-11-12 2002-12-03 Maxygen Holdings Ltd A conjugate exhibiting interferon gamma activity, nucleotide sequence encoding for a polypeptide fraction of conjugate, an expression vector and a host cell containing nucleotide sequence, pharmaceutical composition comprising the same and use thereof
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20030171285A1 (en) 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
IL162031A0 (en) * 2001-11-20 2005-11-20 Pharmacia Corp Chemically-modified human growth hormone conjugates
EP3669887A1 (en) * 2002-01-18 2020-06-24 Biogen MA Inc. Polyalkylene polymer compounds and uses thereof
US7345150B2 (en) * 2002-03-26 2008-03-18 Medical University Of Toledo Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use
AP2005003246A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.
CA2547140A1 (en) * 2003-11-24 2005-06-09 Neose Technologies, Inc. Glycopegylated erythropoietin
EA200700380A1 (ru) 2004-08-31 2007-10-26 Фармация Энд Апджон Компани Ллс Конъюгаты глицеринразветвлённого полиэтиленгликоля - гормона роста человека, способ их получения и способы их применения
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
EP1869079A2 (en) * 2005-03-11 2007-12-26 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
CN101002944B (zh) 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
CN101104078B (zh) 2006-07-11 2011-11-02 北京美倍他药物研究有限公司 多肽及蛋白药物的聚乙二醇偶合物
CN101108895B (zh) 2006-07-19 2011-10-26 北京键凯科技有限公司 聚乙二醇乙醛衍生物及其与药物的结合物
CN1966547B (zh) 2006-11-06 2011-11-09 中国药科大学 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN1970572A (zh) 2006-12-21 2007-05-30 北京三元基因工程有限公司 干扰素α突变体及其聚乙二醇衍生物
CA2698173C (en) 2007-09-04 2015-02-03 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha 2b modified by polyethylene glycol, the preparation and use thereof
CA2698396C (en) 2007-09-04 2014-01-21 Biosteed Gene Expression Tech. Co., Ltd. Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof
CN101491682A (zh) 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101671390B (zh) 2008-09-10 2012-10-03 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
CN101514229B (zh) 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
EP2205281A4 (en) 2014-10-08
AU2008286742B2 (en) 2014-05-29
ZA201001777B (en) 2010-12-29
AR067964A1 (es) 2009-10-28
FR22C1045I2 (fr) 2023-12-29
JP5613050B2 (ja) 2014-10-22
UA103158C2 (ru) 2013-09-25
CN101367872A (zh) 2009-02-18
NL301195I1 (pl) 2022-08-31
WO2009023826A1 (en) 2009-02-19
HUS2200039I1 (hu) 2022-09-28
FR22C1045I1 (fr) 2022-10-14
PT2205281T (pt) 2022-08-02
EA201070282A1 (ru) 2010-08-30
EP2205281B1 (en) 2022-06-29
CL2008002399A1 (es) 2009-01-02
US8143214B2 (en) 2012-03-27
EP2205281A1 (en) 2010-07-14
HRP20220937T3 (hr) 2022-09-30
CA2696478C (en) 2018-10-09
BRPI0814482A2 (pt) 2015-02-03
BRPI0814482B8 (pt) 2021-11-23
BRPI0814482B1 (pt) 2021-02-02
NZ583831A (en) 2012-06-29
TW200916116A (en) 2009-04-16
NL301195I2 (nl) 2023-03-02
US20090053177A1 (en) 2009-02-26
DK2205281T3 (da) 2022-08-15
MX2010001750A (es) 2010-06-01
AU2008286742A1 (en) 2009-02-19
EA018111B1 (ru) 2013-05-30
HUE059551T2 (hu) 2022-11-28
SI2205281T1 (sl) 2022-11-30
LT2205281T (lt) 2022-09-26
KR101588465B1 (ko) 2016-01-25
CA2696478A1 (en) 2009-02-19
ES2924727T3 (es) 2022-10-10
CN101367872B (zh) 2013-11-20
CY1125751T1 (el) 2023-06-09
NO2022038I1 (no) 2022-09-02
EP4129343A1 (en) 2023-02-08
JP2010536788A (ja) 2010-12-02
KR20100076945A (ko) 2010-07-06
MY149148A (en) 2013-07-15
TWI381851B (zh) 2013-01-11

Similar Documents

Publication Publication Date Title
IL211180B (en) Attached polyethylene glycol and docetaxel
GB0817799D0 (en) Luftfiltersystem
AP2010005314A0 (en) Nanodispersian
NL300945I2 (en) Burosumab
HUS2200039I1 (hu) Protein-polimer konjugátumok
IL199718A0 (en) Peptide-complement conjugates
GB0723387D0 (en) Improved dehumldifier
HUE049051T2 (hu) Fehérje-polimer konjugátumok
PL381690A1 (pl) Preparat biobójczy
AU3595P (en) Goldust Strobilanthes anisophyllus
AU3606P (en) Jaywick xTriticosecale
GB0725328D0 (en) Data-handleing means
GB0724415D0 (en) CV-kinisis II
GB0602688D0 (en) Conjugates
GB0720259D0 (en) Eletrcity meeting improvements
GB0711900D0 (en) Ondontalgic preparation
PL381845A1 (pl) Preparat bitumujący
MY152933A (en) Technical field
GB0708496D0 (en) P2
GB0721702D0 (en) Hydrogienic globaltechnology limited
GB0714068D0 (en) No riveal
GB0713975D0 (en) No Riveal
AU320760S (en) Cutsaw
AU314020S (en) Lugagge
AU316644S (en) Bed - AP